Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies: New Directions.
Upper gastrointestinal malignancies generally have moderate to poor cure rates, even in the earliest stages, thereby implying that both local and systemic treatments have room for improvement. Therapeutic options are broadening, however, with the development of new immunotherapies and targeted agents, which can have synergistic effects with radiotherapy. Here we discuss the current state of combined modality therapy for upper gastrointestinal malignancies, specifically recent successes and setbacks in trials of radiation therapy with targeted therapies, vaccines, immunotherapies, and chemotherapies.
Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.
Daniel S
DS
Jamorabo
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Steven H
SH
Lin
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ. Electronic address: jabbousk@cinj.rutgers.edu.
Salma K
SK
Jabbour
D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D005770:Gastrointestinal Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D011878:Radiotherapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D019496:Cancer Vaccines